CClinicalTrials.gg
WithdrawnNCT00954343STUFUpdated Mar 19, 2013

Shockwave Treatment of Diabetic Foot Ulcer: Step I

An interventional study of Extracorporeal Shock Wave and Extracorporeal Shock Wave in Chronic Diabetic Foot Ulcers, sponsored by Technical University of Munich. Withdrawn at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-19.

Sponsored by Technical University of Munich · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Extracorporeal Shock Wave treatment is a well established treatment in orthopedics. Considerable success has been reported after treatment of various soft tissue pathologies (Tendinitis, heel spur etc). In recent years, encouraging results have been reported concerning the effect of the shock-wave on chronic wounds. It has been reported that healing time can be considerably shortened if shock-waves are applied to the wound in addition to conventional wound treatment. Yet, randomized, controlled, prospective trials are missing.

In this study, the effect of shock-waves on diabetic foot ulcer shall be assessed.

The study is composed of 5 groups of which 4 groups receive shock wave treatments (each with a different protocol). One group serves as an untreated control group. All groups get standardized wound treatment and wound dressing.

That shock-wave application protocol that shows the best results (rate of completely healed ulcer, most decrease of ulcer size) shall be tested in a further, sufficiently dimensioned, two-armed, randomized controlled trial (RCT).

02

Conditions studied

  • Chronic Diabetic Foot Ulcers

Keywords

  • Foot Ulcers
  • Extracorporeal Shockwave
  • Chronic wound
03

In context

Diabetic Foot

1,054 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Lead sponsor

Technical University of Munich is the lead sponsor of 315 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 and older
  • Diabetes Type I or II
  • Chronic ulcer on the foot
  • Ulcer present for at least 6 weeks
  • Wagner Grade 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Chronic rest pain
  • Critical ischemia
  • Gangrene
  • Ankle-Arm-Index \< 0,5
  • Critical ischemia treated within 6 weeks before possible enrollment
  • Ulcer of Grade 3 or worse according to the Wagner Classification
  • Osteomyelitis
  • Affection of toes
  • Necessity of surgical intervention
  • Malalignment of the foot sustaining the ulcer
  • Treatment of Ulcer with Prostaglandins or vasodilatators within the last 2 weeks
  • Current therapy with corticoids
  • Infection with HIV; Hepatitis
  • Suppression of immune system (due to illness or medication)
  • Medication with Vitamin-K-Antagonists
  • Known hemophilia
  • Sever Hypalbuminemia \< 2 g/dl
  • Severe anemia
  • Ulcer other than of diabetic origin
  • Pregnant or breast-feeding women
  • Known coagulopathies
  • Implants such as artificial heart valves, joint replacement, bone replacement, osteosynthesis material
  • Patients participating on other studies
  • Chemotherapy within the last 60 days
  • Mentally disabled patients
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group I

    Procedure: Extracorporeal Shock Wave

  • Experimental
    Group II

    Procedure: Extracorporeal Shock Wave

  • Experimental
    Group III

    Procedure: Extracorporeal Shock Wave

  • Experimental
    Group IV

    Procedure: Extracorporeal Shock Wave

  • No intervention
    Group V

Interventions

  • ProcedureExtracorporeal Shock Wave
  • ProcedureExtracorporeal Shock Wave
  • ProcedureExtracorporeal Shock Wave
  • ProcedureExtracorporeal Shock Wave
06

What researchers measure

Primary outcomes

  1. Percentage decrease of ulcer size twelve weeks after treatment begin (i.e. first shock wave treatment) compared to the baseline (ulcer size at first treatment)

Secondary outcomes

  1. Rate of completely healed ulcer 6, 9 and 12 weeks after first treatment

  2. Percentage decrease of ulcer size 6 and 9 weeks after first treatment

  3. Tissue oxygen concentration after shock wave treatment

07

Study locations

1 site
  • Klinik für Orthopädie und Unfallchirurgie, Klinikum rechts der Isar
    Munic, Bavaria 81675, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00954343
Lead sponsor
Technical University of Munich
First posted
Aug 7, 2009
Start date
Aug 2009
Last update
Mar 19, 2013

Study contacts

Hans Gollwitzer, PD Dr., CCRP
principal investigator · Klinik für Orthopädie und Unfallchirurgie Klinikum rechts der Isar

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion